DK116128B - Fremgangsmåde til fremstilling af terapeutisk virksomme 17α-(alkanoyloxy eller cycloalkanoyloxy)-21-(alkanoyloxy eller cycloalkanoyloxy)-16β-methyl-9α-halogen-11β-hydroxy-Δ<1,4>-pregnadien-3,20-dioner. - Google Patents

Fremgangsmåde til fremstilling af terapeutisk virksomme 17α-(alkanoyloxy eller cycloalkanoyloxy)-21-(alkanoyloxy eller cycloalkanoyloxy)-16β-methyl-9α-halogen-11β-hydroxy-Δ<1,4>-pregnadien-3,20-dioner.

Info

Publication number
DK116128B
DK116128B DK291164AA DK291164A DK116128B DK 116128 B DK116128 B DK 116128B DK 291164A A DK291164A A DK 291164AA DK 291164 A DK291164 A DK 291164A DK 116128 B DK116128 B DK 116128B
Authority
DK
Denmark
Prior art keywords
cycloalkanoyloxy
alkanoyloxy
pregnadiene
diones
hydroxy
Prior art date
Application number
DK291164AA
Other languages
English (en)
Inventor
J Elks
P May
N Weir
Original Assignee
Glaxo Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Lab Ltd filed Critical Glaxo Lab Ltd
Publication of DK116128B publication Critical patent/DK116128B/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)
  • Insulated Conductors (AREA)
  • Combinations Of Kitchen Furniture (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK291164AA 1963-06-11 1964-06-10 Fremgangsmåde til fremstilling af terapeutisk virksomme 17α-(alkanoyloxy eller cycloalkanoyloxy)-21-(alkanoyloxy eller cycloalkanoyloxy)-16β-methyl-9α-halogen-11β-hydroxy-Δ<1,4>-pregnadien-3,20-dioner. DK116128B (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB23223/63A GB1047518A (en) 1963-06-11 1963-06-11 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
GB362364 1964-01-28

Publications (1)

Publication Number Publication Date
DK116128B true DK116128B (da) 1969-12-15

Family

ID=26238483

Family Applications (2)

Application Number Title Priority Date Filing Date
DK291064AA DK116205B (da) 1963-06-11 1964-06-10 Analogifremgangsmåde til fremstilling af 17α-alkanoyloxy-9α-halogen-16β-methyl-11β,21-dihydroxy-Δ<1,4>-pregnadien-3,20-dioner.
DK291164AA DK116128B (da) 1963-06-11 1964-06-10 Fremgangsmåde til fremstilling af terapeutisk virksomme 17α-(alkanoyloxy eller cycloalkanoyloxy)-21-(alkanoyloxy eller cycloalkanoyloxy)-16β-methyl-9α-halogen-11β-hydroxy-Δ<1,4>-pregnadien-3,20-dioner.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK291064AA DK116205B (da) 1963-06-11 1964-06-10 Analogifremgangsmåde til fremstilling af 17α-alkanoyloxy-9α-halogen-16β-methyl-11β,21-dihydroxy-Δ<1,4>-pregnadien-3,20-dioner.

Country Status (14)

Country Link
US (1) US3312590A (da)
BE (2) BE649171A (da)
BR (2) BR6459937D0 (da)
CH (2) CH450410A (da)
CY (1) CY544A (da)
DE (2) DE1443958B1 (da)
DK (2) DK116205B (da)
ES (2) ES300811A1 (da)
FR (1) FR4548M (da)
GB (1) GB1047518A (da)
MY (1) MY7000131A (da)
NL (2) NL142157B (da)
NO (2) NO125533B (da)
SE (2) SE313562B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3475466A (en) * 1965-08-30 1969-10-28 Schering Corp Novel 17,21-diesters of 16alpha-methyl-9alpha,11beta-dichloro-1,4- pregnadienes
US3422193A (en) * 1966-08-11 1969-01-14 Schering Corp 17-mono esters of corticoids
IT1061787B (it) * 1967-03-01 1983-04-30 Vismara Francesco Spa Miglioramenti relativi alla preparazione di 17 benzoato di betametazone
GB1281689A (en) * 1968-10-14 1972-07-12 Glaxo Lab Ltd Steroid 21-phosphates
US3694471A (en) * 1970-06-08 1972-09-26 Warner Lambert Pharmaceutical 17-valerate ester of 6{60 ,9{60 -difluorohydrocortisone, its compositions and use as an anti-inflammatory agent
DK135267A (da) * 1971-02-25
US3789121A (en) * 1971-11-26 1974-01-29 Warner Lambert Co 17{60 ,21-orthobutyrates of 6{60 , 9{60 -difluoro-hydrocortisone and 6{60 , 9{60 -difluoroprednisolone, compositions containing same and the use thereof as anti-inflammatory agents
US4044126A (en) * 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
SE418294B (sv) * 1974-03-27 1981-05-18 Plurichemie Anstalt Sett att framstella en 16alfa- eller 16beta-9alfa-klor eller -fluorsteroidester
US4018918A (en) * 1975-05-20 1977-04-19 The Upjohn Company Topical clindamycin preparations
DE2645104C2 (de) * 1976-10-04 1986-04-24 Schering AG, 1000 Berlin und 4709 Bergkamen 11&beta;-Hydroxy-1,4,8-pregnatrien-3,20-dion-Derivate und Verfahren zu ihrer Herstellung
US4070462A (en) * 1976-10-26 1978-01-24 Schering Corporation Steroid ointment
JPS6040439B2 (ja) * 1978-03-29 1985-09-11 大正製薬株式会社 ヒドロコルチゾン誘導体
EP0029924B1 (en) * 1979-11-16 1984-08-15 STEROSYNT Ltd. 6-alpha-fluoro-16-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them
US4350690A (en) * 1980-10-27 1982-09-21 Cressington Investments Ltd. Steroid composition
US4346086A (en) * 1981-06-09 1982-08-24 Beiersdorf Aktiengesellschaft Corticosteroid-containing cream
IL66432A0 (en) * 1981-08-04 1982-12-31 Plurichemie Anstalt Process for the preparation of steroidal esters
DE3133081A1 (de) * 1981-08-18 1983-03-10 Schering Ag, 1000 Berlin Und 4619 Bergkamen Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung
FR2515041A1 (fr) * 1981-10-26 1983-04-29 Besins Jean Medicament a base de progesterone pour le traitement des affections mammaires
EP0095894A3 (en) * 1982-05-31 1985-01-02 Ohta Seiyaku Kabushiki Kaisha. 6 alpha-methylprednisolone derivatives
DE3227312A1 (de) * 1982-07-19 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 6,16-dimethylkortikoide, ihre herstellung und verwendung
DE3243482A1 (de) * 1982-11-22 1984-05-24 Schering AG, 1000 Berlin und 4709 Bergkamen Neue 6(alpha)-methylkortikoide, ihre herstellung und verwendung
US4489070A (en) * 1983-05-13 1984-12-18 Schering Corporation Betamethasone dipropionate cream
US4482539A (en) * 1983-05-13 1984-11-13 Schering Corporation Betamethasone dipropionate cream
DE3400188A1 (de) * 1984-01-02 1985-07-11 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 6(alpha),16(alpha)-dimethylkortikoide
PT78973A (en) * 1984-07-25 1984-08-01 Joao Emerico Villax New preparation process of the 9alpha-fluoro 17,21-acylates or hidroxilades in 17 and 21 chloro-corticosteroid
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
SK280968B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Balenie medikamentu na použite v inhalačnom prístroji
UA26230A (uk) * 1990-03-02 1999-07-19 Глексо Груп Лімітед Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок
US6777399B2 (en) * 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
BRPI0113042B8 (pt) * 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
GB0019172D0 (en) * 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
US6858596B2 (en) * 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
BR0209271A (pt) * 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
US20040248867A1 (en) * 2001-06-12 2004-12-09 Keith Biggadike Novel anti-inflammatory 17.alpha.-heterocyclic-esters of 17.beta.carbothioate androstane derivatives
AU2002356759A1 (en) * 2001-12-01 2003-06-17 Glaxo Group Limited 17.alpha. -cyclic esters of 16-methylpregnan-3,20-dione as anti-inflammatory agents
US20050175545A1 (en) * 2002-02-04 2005-08-11 Keith Biggadike Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
GB0202635D0 (en) * 2002-02-05 2002-03-20 Glaxo Wellcome Mfg Pte Ltd Formulation containing novel anti-inflammatory androstane derivative
GB2389530B (en) * 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
CA2537185A1 (en) * 2003-08-29 2005-03-10 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type-iv
EP1694655A2 (en) * 2003-11-26 2006-08-30 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
US20080009535A1 (en) * 2004-08-30 2008-01-10 Sarala Balachandran Inhibitors of phosphodiesterase type-IV
GB0507165D0 (en) * 2005-04-08 2005-05-18 Glaxo Group Ltd Novel crystalline pharmaceutical product
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
WO2007045979A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
RU2008119322A (ru) * 2005-10-19 2009-11-27 Рэнбакси Лабораториз Лимитед (In) Композиции ингибиторов фосфодиэстеразы iv типа
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
KR20090069309A (ko) * 2006-09-22 2009-06-30 랜박시 래보러터리스 리미티드 포스포디에스터라제 타입-ⅳ의 저해제
WO2008035316A2 (en) * 2006-09-22 2008-03-27 Ranbaxy Laboratories Limited Phosphodiesterase inhibitors
EP1958947A1 (en) 2007-02-15 2008-08-20 Ranbaxy Laboratories Limited Inhibitors of phosphodiesterase type 4
US20110130403A1 (en) * 2007-03-14 2011-06-02 Ranbaxy Laboratories Limited Pyrazolo [3, 4-b] pyridine derivatives as phosphodiesterase inhibitors
NZ579645A (en) 2007-03-14 2012-01-12 Ranbaxy Lab Ltd Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors
US8796248B2 (en) * 2007-10-05 2014-08-05 Nektar Therapeutics Oligomer-corticosteroid conjugates
EP2111861A1 (en) 2008-04-21 2009-10-28 Ranbaxy Laboratories Limited Compositions of phosphodiesterase type IV inhibitors
CN112358522B (zh) * 2020-05-18 2021-11-16 河南利华制药有限公司 一种倍他米松二丙酸酯的精制方法及倍他米松二丙酸酯
CN111944002A (zh) * 2020-07-29 2020-11-17 河南利华制药有限公司 一种倍氯米松二丙酸酯中间体及制备方法
CN116023425B (zh) * 2023-03-28 2023-06-20 南京师范大学 曲安西龙衍生物及其医药用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3147249A (en) * 1961-06-13 1964-09-01 Vismara Francesco Spa 17alpha, 21-substituted methylenedioxy steroids and methods therefor
CH429716A (de) * 1961-06-24 1967-02-15 Vismara Francesco Spa Verfahren zur Herstellung von 17a-Acyloxy-21-hydroxy-Steroiden

Also Published As

Publication number Publication date
SE313562B (da) 1969-08-18
NO125533B (da) 1972-09-25
US3312590A (en) 1967-04-04
NL6406614A (da) 1964-12-14
BR6459937D0 (pt) 1973-08-07
CH450410A (de) 1968-01-31
CH457422A (de) 1968-06-15
SE320066B (da) 1970-02-02
MY7000131A (en) 1970-12-31
DK116205B (da) 1969-12-22
BE649170A (da) 1964-12-11
NL142157B (nl) 1974-05-15
CY544A (en) 1970-07-02
ES300814A1 (es) 1964-12-01
BE649171A (da) 1964-12-11
ES300811A1 (es) 1962-12-16
NO125532B (da) 1972-09-25
DE1443958B1 (de) 1970-01-02
BR6459936D0 (pt) 1973-08-02
GB1047518A (en) 1966-11-02
NL6406615A (da) 1964-12-14
NL141378B (nl) 1974-03-15
DE1443957B1 (de) 1970-01-02
FR4548M (da) 1966-11-02

Similar Documents

Publication Publication Date Title
DK116128B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 17α-(alkanoyloxy eller cycloalkanoyloxy)-21-(alkanoyloxy eller cycloalkanoyloxy)-16β-methyl-9α-halogen-11β-hydroxy-Δ&lt;1,4&gt;-pregnadien-3,20-dioner.
DK129835B (da) Analogifremgangsmåde til fremstilling af 2-chlor-6α-fluor-16α-methyl-pregna-1,4-dien-3,20-dioner.
DK116870B (da) Analogifremgangsmåde til fremstilling af terapeutisk virksomme 11β,21-dihydroxy-3,20-dioxo- eller 21-hydroxy-3,11,20-trioxo-pregna-1,4-dien-(17α 16&amp;alpha,-d)-2&#39;metyloxazoliner eller 21-estere deraf.
DK117563B (da) Analogifremgangsmåde til fremstilling af 17α,21-(1&#39;-alkyl-1&#39;-alkoxy-methylendioxy)-11β-hydroxy-9-α-halogen-16β-methyl-1,4-pregnadien-3,20-dioner.
DK120190B (da) Analogifremgangsmåde til fremstilling af terapeutisk aktive 17-estere af 9α,11β-dihalogen-16α-alkyl-Δ&lt;1,4&gt;-pregnadien-17α,21-diol-3,20-dioner.
DK120337B (da) Fremgangsmåde til fremstilling af terapeutisk aktive 3-keto-6-halogen-9β10α-Δ&lt;4,6&gt;-steroiddiener af androstan- eller pregnanrækken.
DK114690B (da) Fremgangsmåde til fremstilling af terapeutisk virksomt 17α-ethinyl-Δ&lt;1,3,5(10)&gt;-østratrien-3,16α,17β-triol eller estere eller ethere deraf.
DK120701B (da) Analogifremgangsmåde til fremstilling af terapeutisk virksomme 17β-tetrahydropyranylethere af Δ&lt;1,3,5(10)&gt;-østratrien-3-ol-eller 3-ethere eller 3-estere deraf.
DK126111B (da) Fremgangsmåde til fremstilling af Δ&lt;5,10&gt;-steroider med cyclopentanoperhydrophenanthrenstruktur.
DK112235B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 21-dicyclohexylmethylcarbonater af 21-hydroxy-Δ&lt;4&gt;-pregnen-17α-ol-3,20-dioner.
DK114060B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 1,2β-metylensteroider af androstan- eller 9-norandrostanrækken.
DK113146B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 6-halogen-1α,2α-methylen-16α-methyl-&amp;Delta&lt;4,6&gt;-pregnadien-17α-ol-3,20-dioner eller deres 17-estere.
DK111141B (da) Fremgangsmåde til fremstilling af 2&#39;-acetamido-2&#39;-desoxyglucosider eller -galactosider af 17α,21-dihydroxy-11-oxygenerede -3,20-diketo-steroider af pregnanrækken.
DK116658B (da) Fremgangsmåde til fremstilling af terapeutisk aktive 7α-methyl-Δ&lt;5&gt;-østrener.
DK122452B (da) Analogifremgangsmåde til fremstilling af 21-estere af 6α-halogen-16α-methyl-Δ&lt;1,4&gt;-pregnadien-11β,21-diol-3,20-dioner.
DK113640B (da) Analogifremgangsmåde til fremstilling af terapeutisk virksomme 9α,11β-dihalogen-pregna-1,4-dien-[17α,16α-d]-oxazolin-3,20-dioner.
DK132121B (da) Fremgangsmåde til fremstilling af 17alfa-hydroxypregna-4,9(11)-dien-3,20-dion.
DK111615B (da) Fremgangsmåde til fremstilling af 6α,9α-difluor-16α-metyl-Δ&lt;1,4&gt;-pregnadien-11β,21-diol-3,20-dion eller estere deraf.
DK118556B (da) Analogifremgangsmåde til fremstilling af 16α-methyl-9α-chlor-Δ&lt;1,4&gt;-pregnadien-11β,21-diol-3,20-dioner eller 21-estere deraf.
DK123768B (da) Analogifremgangsmåde til fremstilling af terapeutisk aktive 6-halogeno-9β, 10α-Δ&lt;1,4&gt;, Δ&lt;4,6&gt;- eller Δ &lt;1,4,6&gt;- pregnen-3,20-dioner eller tilsvarende 3-alkoxy-Δ&lt;3,5&gt;- derivater deraf.
DK114832B (da) Fremgangsmåde til fremstilling af terapeutisk aktive 3β-hydroxy-16α-alkyl-δ&lt;4&gt;-pregnenderivater eller estere deraf.
DK123767B (da) Fremgangsmåde til fremstilling af diastereomere 2β,3β,14α,22,25-pentahydroxy-Δ&lt;7&gt;-cholesten-6-oner eller blandinger deraf.
DK118716B (da) Analogifremgangsmåde til fremstilling af terapeutisk aktive 6α-methyl-16-methylen-Δ&lt;4&gt;-ostren-17β-oler eller estere deraf.
DK112380B (da) Fremgangsmåde til fremstilling af 6-methyl-3-oxo-Δ&lt;4,7&gt;-steroider af pregnanrækken.
DK112168B (da) Fremgangsmåde til fremstilling af terapeutisk virksomme 17-estere af 16α-halogen-6α-methyl-17α-hydroxy-4-pregnen-3,20-dioner.